Cargando…
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
Postzygotic mutations of the PIK3CA [phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha] gene constitutively activate the PI3K/AKT/mTOR pathway in PIK3CA-related overgrowth spectrum (PROS) patients, causing congenital mosaic tissue overgrowth that even multiple surgeries cannot s...
Autores principales: | Ranieri, C., Di Tommaso, S., Loconte, D. C., Grossi, V., Sanese, P., Bagnulo, R., Susca, F. C., Forte, G., Peserico, A., De Luisi, A., Bartuli, A., Selicorni, A., Melis, D., Lerone, M., Praticò, A. D., Abbadessa, G., Yu, Y., Schwartz, B., Ruggieri, Martino, Simone, Cristiano, Resta, Nicoletta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956072/ https://www.ncbi.nlm.nih.gov/pubmed/29549527 http://dx.doi.org/10.1007/s10048-018-0540-1 |
Ejemplares similares
-
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015) -
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017) -
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015) -
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
por: Biesecker, Leslie G., et al.
Publicado: (2020)